Celiac disease in chronic hepatitis C patients under pegylated-interferon plus ribavirin treatment. Preliminary results of a prospective single center study.
Elefsiniotis
Ioannis S
IS
Fotos
Nikolaos V
NV
Pantazis
Konstantinos D
KD
Papadeli
Despina
D
Mavrogiannis
Christos
C
D000328:Adult; D000906:Antibodies / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D002446:Celiac Disease / Q000150:complications*; D005260:Female; D005903:Gliadin / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011446:Prospective Studies; D012254:Ribavirin / Q000627:therapeutic use*; D011503:Transglutaminases / Q000276:immunology
D000906:Antibodies; D000998:Antiviral Agents; D016898:Interferon-alpha; D011092:Polyethylene Glycols; D012254:Ribavirin; D005903:Gliadin; D011503:Transglutaminases